Summary, Highlights & Graphical Abstract (cc-structured-abstract)
When to trigger
- Need a Cancer Cell Summary (the abstract)
- Need Highlights (the short bullet list Cell Press requires)
- Need the eTOC blurb (one-paragraph teaser for the table of contents)
- Building or refining the graphical abstract
The Summary (abstract)
Cell Press uses a single-paragraph Summary (verify the current word limit on the author page). Structure it as a tight mechanistic arc:
- Context / gap — the cancer problem and the unknown (1 sentence).
- Approach — the systems used (cells / in vivo / human), at a high level.
- Core finding — the mechanism: what regulates what, with direction.
- Validation — that it holds in vivo and/or in patient data.
- Significance — the translational implication (vulnerability / biomarker / therapy), calibrated to the evidence.
Lead with the discovery, not the background. Name the molecule/axis and the cancer context concretely. Avoid hype words ("novel," "unprecedented") and unsupported clinical promises.
Highlights
- Provide the required number of short bullets (commonly four; verify current count), each ~85 characters.
- Each highlight is a result, not a method or aim.
- Order them as a mini-story: key mechanism → validation → translational point.
- Make them specific and declarative ("X drives Y via Z in pancreatic tumors"), not vague ("X plays a role").
eTOC blurb
- One short paragraph (a few sentences) written for a broad cancer audience.
- Third person, present tense; names the authors' key finding and why it matters.
- Often written as "Author et al. show that ..." — confirm the current style.
- No abbreviations that a non-specialist would not know.
Graphical abstract
- One panel that conveys the mechanism and its consequence at a glance.
- Show the axis (input → node → output) and the tumor context; minimal text.
- Must match the paper's actual claims — no implied results beyond the data.
- Build in BioRender/Illustrator at required resolution; legible at thumbnail size.
Checklist
Anti-patterns
- Background-heavy Summary that buries the finding
- Highlights that restate aims/methods or are vague
- Overclaiming therapeutic impact in the Summary or graphical abstract
- Graphical abstract implying results not shown in the paper
- eTOC blurb stuffed with jargon and abbreviations
- Inconsistent gene/protein nomenclature across front matter and text
Abstract pass for Cancer Cell
Use this as a second-pass capability check. First lock the cancer context, mechanism, model system, validation chain, and translational boundary; then test whether the manuscript addresses cancer-biology reviewers who expect mechanistic oncology, translational relevance, and strong multi-modal validation.
- Primary move: Compress to question, design, population/object, result, limitation, and contribution; remove generic importance sentences.
- Decision ledger: return
claim / evidence / blocker / next edit rows so the next pass can patch the manuscript directly.
- Neighbor test: compare against Cell for broader biology, Nature Cancer for oncology breadth, Clinical Cancer Research for clinical translation; if the neighboring outlet has the stronger audience claim, recommend re-routing before polishing.
- Verification floor: before submission-ready advice, re-open
resources/official-source-map.md for volatile rules and name the one unresolved fact that could change the recommendation.
Output format
【Summary】drafted; words = ...; leads with finding? Y/N
【Validation line】in vivo / human stated? Y/N
【Highlights】n bullets; all results? within length?
【eTOC blurb】broad-audience? accurate? Y/N
【Graphical abstract】mechanism→consequence? matches data? Y/N
【Overclaim check】hype/clinical promises removed? Y/N
【Next step】cc-ethics-registration or cc-writing-style
1---2name: cc-structured-abstract3description: Use when writing the Cancer Cell (Cell Press) front matter — the Summary, eTOC blurb, Highlights, and graphical abstract. It crafts these short items for accuracy and impact; it does not write Results or calibrate statistics.4metadata:5 source: https://skillmd.com/skills/brycewang-stanford/cc-structured-abstract6---78# Summary, Highlights & Graphical Abstract (cc-structured-abstract)910## When to trigger1112- Need a Cancer Cell **Summary** (the abstract)13- Need **Highlights** (the short bullet list Cell Press requires)14- Need the **eTOC blurb** (one-paragraph teaser for the table of contents)15- Building or refining the **graphical abstract**1617## The Summary (abstract)1819Cell Press uses a single-paragraph **Summary** (verify the current word limit on the author page). Structure it as a tight mechanistic arc:20211. **Context / gap** — the cancer problem and the unknown (1 sentence).222. **Approach** — the systems used (cells / in vivo / human), at a high level.233. **Core finding** — the mechanism: what regulates what, with direction.244. **Validation** — that it holds in vivo and/or in patient data.255. **Significance** — the translational implication (vulnerability / biomarker / therapy), calibrated to the evidence.2627Lead with the discovery, not the background. Name the molecule/axis and the cancer context concretely. Avoid hype words ("novel," "unprecedented") and unsupported clinical promises.2829## Highlights3031- Provide the required number of short bullets (commonly four; verify current count), each ~85 characters.32- Each highlight is a **result**, not a method or aim.33- Order them as a mini-story: key mechanism → validation → translational point.34- Make them specific and declarative ("X drives Y via Z in pancreatic tumors"), not vague ("X plays a role").3536## eTOC blurb3738- One short paragraph (a few sentences) written for a broad cancer audience.39- Third person, present tense; names the authors' key finding and why it matters.40- Often written as "Author et al. show that ..." — confirm the current style.41- No abbreviations that a non-specialist would not know.4243## Graphical abstract4445- One panel that conveys the **mechanism and its consequence** at a glance.46- Show the axis (input → node → output) and the tumor context; minimal text.47- Must match the paper's actual claims — no implied results beyond the data.48- Build in BioRender/Illustrator at required resolution; legible at thumbnail size.4950## Checklist5152- [ ] Summary leads with the discovery and names the mechanism concretely53- [ ] Summary states orthogonal validation (in vivo / human) and a calibrated significance line54- [ ] Summary within the current word limit; no hype words55- [ ] Highlights are results, specific, ordered as a story, within length56- [ ] eTOC blurb is broad-audience, present tense, accurate57- [ ] Graphical abstract shows mechanism → consequence and matches the data58- [ ] Front matter is consistent with the paper's actual claims and `n`/evidence5960## Anti-patterns6162- Background-heavy Summary that buries the finding63- Highlights that restate aims/methods or are vague64- Overclaiming therapeutic impact in the Summary or graphical abstract65- Graphical abstract implying results not shown in the paper66- eTOC blurb stuffed with jargon and abbreviations67- Inconsistent gene/protein nomenclature across front matter and text686970## Abstract pass for Cancer Cell7172Use this as a second-pass capability check. First lock the cancer context, mechanism, model system, validation chain, and translational boundary; then test whether the manuscript addresses cancer-biology reviewers who expect mechanistic oncology, translational relevance, and strong multi-modal validation.7374- **Primary move:** Compress to question, design, population/object, result, limitation, and contribution; remove generic importance sentences.75- **Decision ledger:** return `claim / evidence / blocker / next edit` rows so the next pass can patch the manuscript directly.76- **Neighbor test:** compare against Cell for broader biology, Nature Cancer for oncology breadth, Clinical Cancer Research for clinical translation; if the neighboring outlet has the stronger audience claim, recommend re-routing before polishing.77- **Verification floor:** before submission-ready advice, re-open `resources/official-source-map.md` for volatile rules and name the one unresolved fact that could change the recommendation.7879## Output format8081```82【Summary】drafted; words = ...; leads with finding? Y/N83【Validation line】in vivo / human stated? Y/N84【Highlights】n bullets; all results? within length?85【eTOC blurb】broad-audience? accurate? Y/N86【Graphical abstract】mechanism→consequence? matches data? Y/N87【Overclaim check】hype/clinical promises removed? Y/N88【Next step】cc-ethics-registration or cc-writing-style89```